Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
← catalyst calendarNCT07220460 · readout ≤ 254 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
200estimated
Sites
49
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bipolar I or II Disorder
Intervention
- Drug: ABBV-932
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events
measured Up to approximately 29 weeks
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
measured Up to week 26
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
measured Up to week 26
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
measured Up to week 26
Change From Baseline in Simpson-Angus Scale (SAS)
measured Up to week 26
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
measured Up to week 26
Change From Baseline in Barnes Akathisia Rating Scale (BARS)
measured Up to week 26
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
measured Up to week 26
Change From Baseline in the Epworth Sleepiness Scale (ESS)
measured Up to week 26
Change From Baseline in the Young Mania Rating Scale (YMRS)
measured Up to week 26
Number of Participants with Abnormal Change in Ocular Examination
measured Up to week 26
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed